Nathan Dowden

Salesforce Mimecast Outlook Microsoft Office 365 DigitalOcean Google Analytics Greenhouse.io Nginx Vimeo reCAPTCHA New Relic Google Tag Manager Mobile Friendly Google Font API Remote

biotechnology: pharmaceutical preparations health care biotechnology research intracellular therapeutics endosomal escape vehicle eev platform duchenne muscular dystrophy myotonic dystrophy type 1 therapeutic potential modular approach hemophilia treatment neuromuscular diseases innovative drug delivery oligonucleotide programs antibody-based therapies enzyme therapy cyclic peptides cell-penetrating peptides targeted protein therapy rare diseases biologics therapeutic index cellular penetration genetic disorders dystrophin production therapeutic efficacy patient-centric treatments clinical trials safety & tolerability neurodegenerative diseases biotechnology drug discovery functional dystrophin muscle wasting rna therapy pharmaceutical research disease-causing targets immune-mediated diseases speed to market patient advocacy equity in healthcare inclusive research clinical-stage development biopharmaceutical innovation target engagement pipeline expansion advanced therapies customized treatment programs sustainable healthcare solutions collaborative research diversity in biotech scientific excellence clinical-stage eev therapeutics intracellular delivery rare genetic diseases neuromuscular disorders oligonucleotide therapies immunology oncology central nervous system therapeutic innovation drug development healthcare providers patient-centric strategic partnerships vertex pharmaceuticals pierrepont therapeutics transformative therapies unmet medical needs biopharmaceutical industry innovative treatments genetic therapies healthcare engagement market research targeted marketing key opinion leaders modular platform disease focus areas health wellness & fitness hospital & health care